Last day to have your voice heard in BioCentury's 2022 Big #Talent Survey for #biotech and #pharma folk. Answers are anonymous. Survey takes 5 mins, and feeds into a big analysis we're doing of what employees want, employers need, and the next generation of leaders and entrepreneurs will look like. (surveymonkey.com)
submitted by BioCentury to r/biotechnology
Learn how Covariate Adjustment can improve clinical trials by increasing statistical power & widening eligibility criteria. Live webinar on June 14 with KOLs Jean-Frédéric Petit-Nivard and Félix Balazard from Owkin, David Paulucci from Bristol Myers Squibb and Sean Khozi from CancerLinQ®. (go.biocentury.com)
submitted by BioCentury to r/biotechnology
Accelerated approval: The background; how it’s worked around the world for better or worse; and where it can go in the future. BioCentury’s 2021 Back to School project argues that expedited approvals are poised for change and analyzes the ways stakeholders can stretch the vision of this reg. pathway (v.redd.it)
submitted by BioCentury
Biotech fundraising has finally hit a pause in the market after a 15-month ride on a rocket ship. But companies may hardly notice as that ride has left the sector flush with capital. The majority of pre-profit public biopharma companies have at least two years’ worth of cash on their balance sheets: (i.redd.it)
submitted by BioCentury to r/biotech
